Why the study?
High rates of oral anticoagulant-related adverse events early after hospital discharge support identifying clinical and continuity of care predictors among seniors.
What are the clinical and continuity of care predictors of oral anticoagulant-associated adverse events within 30 days in seniors discharged from the hospital?
What are the clinical and continuity of care predictors of oral anticoagulant-associated adverse events within 30 days in seniors discharged from the hospital?
This study protocol describes a retrospective cohort analysis to identify predictors of early adverse events in older adults discharged on oral anticoagulants.
Answers are grounded in this paper and cite their sources.
May identify post-discharge OAC risk predictors in seniors; leaves open whether interventions will reduce events.
INTRODUCTION: Oral anticoagulants (OACs) are widely prescribed in older adults. High OAC-related adverse event rates in the early period following hospital discharge argue for an analysis to identify predictors. Our objective is to identify and validate clinical and continuity of care variables among seniors discharged from hospital on an OAC, which are independently associated with OAC-related adverse events within 30 days. METHODS AND ANALYSIS: We propose a population-based retrospective cohort study of all adults aged 66 years or older who were discharged from hospital on an OAC from September 2010 to March 2015 in Ontario, Canada. The primary outcome is a composite of the first hospitalisation or emergency department visit for a haemorrhage or thromboembolic event or mortality within 30 days of hospital discharge. A Cox proportional hazards model will be used to determine the association between the composite outcome and a set of prespecified covariates. A split sample method will be adopted to validate the variables associated with OAC-related adverse events. ETHICS AND DISSEMINATION: The use of data in this project was authorised under section 45 of Ontario's Personal Health Information Protection Act, which does not require review by a research ethics board. Results will be disseminated via peer-reviewed publications and presentations at conferences and will determine intervention targets to improve OAC management in upcoming randomised trials. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT02777047; Pre-results.
No takes yet. Share an insight, caveat, or question.
Benipal et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: